6.36
Schlusskurs vom Vortag:
$4.65
Offen:
$4.56
24-Stunden-Volumen:
7.72M
Relative Volume:
5.21
Marktkapitalisierung:
$301.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.21M
KGV:
-36.66
EPS:
-0.1735
Netto-Cashflow:
$-3.31M
1W Leistung:
+132.12%
1M Leistung:
+163.90%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Firmenname
Polaryx Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare PLYX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PLYX
Polaryx Therapeutics Inc
|
6.36 | 220.15M | 0 | -8.21M | -3.31M | -0.1735 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Eingeleitet | Maxim Group | Buy |
Polaryx Therapeutics Inc Aktie (PLYX) Neueste Nachrichten
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events - Bitget
Biotech backs Krabbe families with research summit and Putt-Putt event - Stock Titan
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? - Asianet Newsable
Polaryx Therapeutics, Inc.Common Stock (Nasdaq:PLYX) Stock Quote - The Chronicle-Journal
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
Polaryx Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PLYX | US73110F1003 - marketscreener.com
Polaryx commits to patients with rare pediatric lysosomal storage disorders - TipRanks
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
Maxim starts Polaryx at Buy, sees PLX-200 as differentiated - TipRanks
PLYX | Polaryx Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders - Bitget
PLYX | Polaryx Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Mstone Partners Healthcare Highlights Polaryx Therapeutics’ Latest Preclinical Data Shared at WORLDSymposium™ - EIN News
Polaryx Therapeutics (PLYX) 10K Form and SEC Filings 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Forecast and Price Target 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Price, News & Analysis - MarketBeat
Top Polaryx Therapeutics (PLYX) Competitors 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat
Insider Buying: G. Landis Acquires Shares of Polaryx Therapeutics Inc (PLYX) - GuruFocus
PLYX Stock Price, News & Analysis - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
What's Going On With Polaryx Therapeutics Stock Wednesday? - Benzinga
Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Polaryx selects CRO for phase 2 trial of rare disease treatment - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans - Bitget
SMJ INTERNATIONAL HOLDINGS INC. (SMJF) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx Therapeutics Surges Amid Strategic Market Moves - StocksToTrade
Polaryx Therapeutics Sees Strategic Moves Amid Market Volatility - timothysykes.com
Polaryx selects CRO for Soteria Phase 2 trial - TipRanks
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial - The Manila Times
Polaryx Therapeutics selects contract research organization for Soteria phase 2 basket trial - marketscreener.com
Rare-disease biotech readies Phase 2 trial across four childhood disorders - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
FORTUNE BRANDS INNOVATIONS, INC. (FBIN) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx Therapeutics, Inc. Rings the Closing Bell - Nasdaq
NUSCALE POWER CORPORATION (SMR) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx to evaluate PLX-200 for Krabbe disease in Phase 2 trial - Investing.com South Africa
Polaryx announces pre-clinical data related to Soteria - TipRanks
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ - The Manila Times
In mice with Krabbe disease, Polaryx drug restored movement, extended life - Stock Titan
Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings - Benzinga
Morning Market Movers: UOKA, KD, HIMS, PGY See Big Swings - RTTNews
Strategy, Bitmine Immersion Technologies And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Finanzdaten der Polaryx Therapeutics Inc-Aktie (PLYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):